Scilex Holding (SCLX) Non-Current Assets (2020 - 2026)

Scilex Holding (SCLX) posted quarterly Non-Current Assets of $1.5 million for Q1 2026, up 1201.68% year-over-year from $119000.0 in Q1 2025, and up 196.18% on a QoQ basis from $523000.0 in Q4 2025.

Scilex Holding (SCLX) Non-Current Assets (2020 - 2026) Analysis & Trends

Scilex Holding (SCLX) has reported Non-Current Assets for 7 consecutive years, with $1.5 million the latest figure, recorded in Q1 2026.

  • In Q1 2026, Non-Current Assets rose 1201.68% year-over-year to $1.5 million; the TTM figure through Mar 2026 stood at $1.5 million (up 1201.68% YoY), while the FY2025 annual figure was $523000.0, up 339.5% from the prior year.
  • Non-Current Assets came in at $1.5 million for Q1 2026 at Scilex Holding, up from $523000.0 in the prior quarter.
  • The five-year high for Non-Current Assets was $141.7 million in Q2 2022, with the low at $119000.0 in Q4 2024.
  • Average Non-Current Assets over 5 years is $23.6 million, with a median of $944000.0 recorded in 2022.
  • Across the five-year window, Non-Current Assets plunged 99.89% in 2023 and jumped 4814.46% in 2024, its largest moves.
  • Year by year, Non-Current Assets stood at $944000.0 in 2022, then declined by 4.98% to $897000.0 in 2023, then tumbled by 86.73% to $119000.0 in 2024, then surged by 339.5% to $523000.0 in 2025, then soared by 196.18% to $1.5 million in 2026.
  • According to Business Quant data, Non-Current Assets over the past three periods registered $1.5 million, $523000.0, and $119000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non-Current Assets (Qtr)
1 Eli Lilly 1,066.16 Bn 1,060.88 Bn 16.22 Bn 61.74 Bn
2 Johnson & Johnson 611.69 Bn 589.64 Bn 15.96 Bn 141.72 Bn
3 AbbVie 444.34 Bn 434.99 Bn 10.78 Bn 102.93 Bn
4 Astrazeneca 284.94 Bn 277.05 Bn 12.61 Bn 84.40 Bn
5 Merck 224.23 Bn 218.58 Bn 12.09 Bn 125.00 Mn
6 Amgen 195.12 Bn 183.08 Bn 5.87 Bn 61.03 Bn
7 Gilead Sciences 156.45 Bn 148.73 Bn 5.52 Bn 37.64 Bn
8 Pfizer 136.01 Bn 123.24 Bn -1.21 Bn 165.18 Bn
9 Novartis Ag 113.45 Bn 113.67 Bn - -
10 Scilex Holding 54.30 Mn -95.62 Mn 4.15 Mn 1.55 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 1.55 Mn
Dec 31, 2025 523,000.00
Sep 30, 2025 119,000.00
Jun 30, 2025 119,000.00
Mar 31, 2025 119,000.00
Dec 31, 2024 119,000.00
Sep 30, 2024 8.16 Mn
Jun 30, 2024 2.90 Mn
Mar 31, 2024 1.08 Mn
Dec 31, 2023 897,000.00
Sep 30, 2023 166,000.00
Jun 30, 2023 1.14 Mn
Mar 31, 2023 153,000.00
Dec 31, 2022 944,000.00
Sep 30, 2022 101.29 Mn
Jun 30, 2022 141.69 Mn
Mar 31, 2022 140.45 Mn
Dec 31, 2021 538,000.00
Sep 30, 2021 139.41 Mn
Jun 30, 2021 139.41 Mn